Study Title

informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia


To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes.


At least 18 years of age

Clinical diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL)

Beginning treatment within +/- 30 days of enrollment

Willing & able to provide written informed consent

Willing & able to complete patient reported outcome questionnaires

Willing & able to provide information on patient survey questionnaires

Willing to provide a blood sample at time of enrollment

You Cannot:           

Be diagnosed with any B-Cell malignancy other than CLL/SLL

Have a life expectancy of less than 6 months

Study Process

Relevant data will be retrieved from the patient medical record & recorded into the registry electronic case report forms along with the completion of the patient reported outcome quesationniare :


Every 3 months for the 1st 6 months

Every 6 months thereafter for a minimum of 2 years

Interested in more information on this clinical research study?

Contact WK Cancer Center Clinical Research Department at 318-212-8671

Trial Details



Advarra Institutional Review Board

IRB Number:

Trial Type:



Pharmacyclics LLC

Contact Information:

Hematology Oncology Associates